So, here's a fun way to start your week: you're a massive health insurer, and the federal government just told you to stop signing up new customers for one of your most important products. That's the Monday Elevance Health Inc. (ELV) is having, with its stock trading notably lower after the Centers for Medicare & Medicaid Services (CMS) decided to freeze enrollment into the company's Medicare Advantage plans.

The Regulatory Freeze Is On

On Friday, CMS sent Elevance a notice. The gist? The agency intends to impose what it calls "intermediate sanctions." This means suspending the enrollment of new Medicare beneficiaries into Elevance's Medicare Advantage-Prescription Drug (MA-PD) plans. It also means putting a stop to certain marketing and communication activities aimed at Medicare beneficiaries.

The important date to circle is March 31, 2026. That's when these sanctions are scheduled to kick in, unless CMS decides before then that Elevance has fixed the problems it's identified. For current members of these plans, it's business as usual—their benefits aren't affected. This is about stopping the flow of new people into the plans, not kicking anyone out.

The Root of the Problem: A Stubborn USB Drive Habit

So, what did Elevance do to warrant this? According to an SEC filing the company made on Friday, CMS says the proposed sanctions relate to "alleged noncompliance" with Medicare Advantage risk adjustment data submission requirements. This isn't about recent slip-ups; it's about data for services provided before April 3, 2023.

Here's where it gets a bit technical, but also a bit baffling. Risk adjustment is a core part of how Medicare Advantage works. Insurers get paid more to cover sicker patients, and they submit diagnosis codes to justify those higher payments. The system only works if the data is accurate and submitted correctly.

According to the CMS notice, here's Elevance's alleged misstep: Since November 2018, the company has not been correcting unsupported diagnosis codes through CMS's mandated electronic systems. Instead, Elevance has repeatedly submitted this correction data via... encrypted external USB drives.

Yes, USB drives. In 2025.

CMS has apparently been telling the company, clearly and repeatedly, that this method is not acceptable. Yet, the notice states that Elevance continued the practice as recently as October 10, 2025. The company says it revised its practices back in April 2023 after getting new regulatory guidance, but evidently, the old habit of the USB drive submission for corrections was a hard one to break.

Elevance says it is "engaging with CMS" and is "committed to working cooperatively" to address the concerns. They have a couple of years to sort it out before the enrollment freeze actually starts.

Adding to the Headaches: A Soft Outlook for 2026

This regulatory news lands at an already tricky time for the insurer. Back in January, Elevance reported its fourth-quarter 2025 results and gave its outlook for 2026. The picture wasn't exactly rosy.

For Q4 2025, revenue came in at $49.3 billion. That was up 10% year-over-year, but it still missed the Wall Street consensus estimate of $49.82 billion. For the full year 2025, operating revenue was a hefty $197.6 billion, up 13%.

The real sting was in the guidance. For fiscal 2026, Elevance expects adjusted earnings to be at least $25.50 per share. The problem? Wall Street analysts were expecting about $26.90. The company also forecast that 2026 sales would decline in the mid-single digits, blaming lower premiums.

The Bigger Picture: Medicare Advantage Under Pressure

Elevance's specific USB-drive drama is playing out against a backdrop of broader pressure on the entire Medicare Advantage program. Also in January, CMS outlined its proposed payment policy updates for Medicare Advantage plans for 2027.

The key takeaway for the industry was modest growth. If finalized, the proposals would result in a net average year-over-year payment increase of a mere 0.09%. While that still translates to over $700 million in additional payments to plans, it's well below the 4%-6% rate of increase the industry had been expecting. CMS framed the changes as emphasizing program sustainability, accuracy, and simplicity.

So, for Elevance and its peers, the regulatory environment is getting stricter on two fronts: how they submit their data *and* how much they get paid. It's a one-two punch of administrative scrutiny and financial pressure.

ELV Price Action: Investors were not thrilled with Monday's news. Elevance Health shares were down 7.23% at $296.88 at the time of publication, according to market data.